利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.025 秒)

    Air conditioner
    1.
    发明授权
    Air conditioner 失效
    冷气机

    公开(公告)号：US06708505B2

    公开(公告)日：2004-03-23

    申请号：US10197460

    申请日：2002-07-18

    申请人： Hiroo Nakamura ,  Hidenori Yokoyama ,  Masayuki Nonaka ,  Atsushi Ohtsuka ,  Tsutomu Kurokawa

    发明人： Hiroo Nakamura ,  Hidenori Yokoyama ,  Masayuki Nonaka ,  Atsushi Ohtsuka ,  Tsutomu Kurokawa

    IPC分类号： F25B4900

    CPC分类号： G06F8/65 ,  F24F11/30 ,  F24F11/58 ,  F24F11/62

    摘要： An air conditioner and a control software updating system capable of easily updating and adding control software desired by a customer. An internet system including telephones and/or personal computers is provided between a service center and customers. Each of air conditioners is provided with a connection terminal for connection to a communication terminal. Software for controlling operation of the air conditioner is updated by using the internet or a memory card after explaining a control software to the customer and confirming the customer's desire.

    摘要翻译： 一种空调和控制软件更新系统，能够容易地更新和添加客户所需的控制软件。 在服务中心和客户之间提供包括电话和/或个人计算机的互联网系统。 每个空调设置有连接到通信终端的连接终端。 用于控制空调的操作的软件在向客户解释控制软件并确认客户的愿望之后通过使用因特网或存储卡来更新。

    Xanthene derivatives, their production and use
    2.
    发明授权
    Xanthene derivatives, their production and use 失效
    呫吨衍生物，其生产和使用

    公开(公告)号：US06221637B1

    公开(公告)日：2001-04-24

    申请号：US08812946

    申请日：1997-03-04

    申请人： Tsuneaki Hida ,  Masahiko Hattori ,  Tsutomu Kurokawa ,  Atsushi Nakanishi

    发明人： Tsuneaki Hida ,  Masahiko Hattori ,  Tsutomu Kurokawa ,  Atsushi Nakanishi

    IPC分类号： C12P1702

    CPC分类号： C07D405/12 ,  C07D311/82 ,  C07D311/86 ,  C07D407/04 ,  C07D409/04 ,  C07K14/70521

    摘要： Xanthene compounds represented by the formula: wherein R1 is a carboxyl group which may be esterified or amidated; R2 is a hydrogen atom, a hydroxyl group, or a hydrocarbon group which may be substituted; R3 and R4 are the same or different and are a hydroxyl group which may be substituted; R5 and R6 are a hydrogen atom or a halogen atom; R7 is a hydrogen atom, a nitro group, a halogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; n is an integer of 0 to 2; and Y is an oxygen atom or two hydrogen atoms; and when n is 0, R2 may be a group represented by the formula: wherein the symbols have the same meanings as defined above, or a salt thereof inhibit a binding of B7-1 to CD28, prevent the B7-1-dependent activation of T cells and inhibit IL-2 production from T cells, thus being used as an immunomodulator such as a graft rejection inhibitor or a pharmaceutical composition for therapeutic treatment of allergy, rheumatoid arthritis, autoimmune disease, nephritis, diabetes mellitus and so on.

    摘要翻译： 由下式表示的呫吨化合物：其中R1是可被酯化或酰胺化的羧基; R2是氢原子，羟基或可被取代的烃基; R3和R4相同或不同，为可被取代的羟基; R5和R6是氢原子或卤素原子; R7是氢原子，硝基，卤素原子，可被取代的烃基，可被取代的杂环基或可被取代的酰基; n为0〜2的整数， Y是氧原子或两个氢原子; 当n为0时，R2可以是由下式表示的基团：其中符号具有与上述相同的含义，或其盐抑制B7-1与CD28的结合，防止B7-1依赖性的活化 T细胞，抑制T细胞的IL-2产生，作为免疫调节剂，例如移植排斥抑制剂或用于治疗过敏，类风湿性关节炎，自身免疫性疾病，肾炎，糖尿病等的药物组合物。

    Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof
    4.
    发明授权
    Antibodies to peptides having NGF-like activity, said antibodies having no substantial cross-reactivity with NGF, and use thereof 失效
    具有NGF样活性的肽的抗体，所述抗体与NGF无相当的交叉反应性及其用途

    公开(公告)号：US5656435A

    公开(公告)日：1997-08-12

    申请号：US350214

    申请日：1994-12-06

    申请人： Kazuo Nakahama ,  Tsunehiko Fukuda ,  Tsutomu Kurokawa ,  Ken-ichi Kuroshima

    发明人： Kazuo Nakahama ,  Tsunehiko Fukuda ,  Tsutomu Kurokawa ,  Ken-ichi Kuroshima

    IPC分类号： C07K14/48 ,  C07K16/22 ,  C12P21/08 ,  G01N33/53 ,  C12N5/20

    CPC分类号： C07K14/48 ,  C07K16/22

    摘要： Disclosed are (A) an antibody to a peptide including at least 8 successive amino acids of an amino acid sequence represented by formulaTyrAlaGluHisLysSerHisArgGlyGluTyrSerValCys AspSerGluSerLeuTrpValThrAspLysSerSerAlaIle AspIleArgGlyHisGlnValThrValLeuGlyGluIleLys ThrGlyAsnSerProValLysGlnTyrPheTyrGluThrArg CysLysGluAlaArgProValLysAsnGlyCysArgGlyIle AspAspLysHisTrpAsnSerGlnCysLysThrSerGlnThr TyrValArgAlaLeuThrSerGluAsnAsnLysLeuValGly TrpArgTrpIleArgIleAspThrSerCysValCysAlaLeu SerArgLysIleGlyArg[1],wherein said antibody has no substantial cross-reactivity with human NGF,(B) a method for producing the antibody, (C) a cloned hybridoma which produces the antibody, (D) a method for producing the cloned hybridoma, (E) a partial peptide of a polypeptide (I) including an amino acid sequence represented by formula (1), (F) a conjugate of a peptide including at least 8 successive amino acids of formula (1) with a carrier protein, (G) a method for purifying the polypeptide (I) and (H) a method for detecting and assaying the polypeptide (I).

    摘要翻译： 所公开的是（A）的抗体的肽，包括由formulaTyrAlaGluHisLysSerHisArgGlyGluTyrSerValCys AspSerGluSerLeuTrpValThrAspLysSerSerAlaIle AspIleArgGlyHisGlnValThrValLeuGlyGluIleLys ThrGlyAsnSerProValLysGlnTyrPheTyrGluThrArg CysLysGluAlaArgProValLysAsnGlyCysArgGlyIle AspAspLysHisTrpAsnSerGlnCysLysThrSerGlnThr TyrValArgAlaLeuThrSerGluAsnAsnLysLeuValGly TrpArgTrpIleArgIleAspThrSerCysValCysAlaLeu SerArgLysIleGlyArg [1]表示的氨基酸序列的至少8种连续氨基酸，其中所述抗体不具有实质性的交叉反应性的人NGF， （B）产生抗体的方法，（C）产生抗体的克隆杂交瘤，（D）克隆的杂交瘤的制备方法，（E）多肽（I）的部分肽，其包含氨基酸序列 通式（1），（F）包含式（1）的至少8个连续氨基酸的肽与载体蛋白的缀合物，（G）纯化多肽（I）的方法和（H） 检测和测定多肽（I）。

    Glia activating factor and its production
    8.
    发明授权
    Glia activating factor and its production 失效
    胶质激活因子及其生产

    公开(公告)号：US5512460A

    公开(公告)日：1996-04-30

    申请号：US340820

    申请日：1994-11-17

    申请人： Ken-ichi Nauro ,  Chisako Seko ,  Tsutomu Kurokawa ,  Tatsuya Kondo

    发明人： Ken-ichi Nauro ,  Chisako Seko ,  Tsutomu Kurokawa ,  Tatsuya Kondo

    IPC分类号： A61K38/00 ,  A61P25/00 ,  A61P43/00 ,  C07K14/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/52 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12R1/19 ,  C12R1/91 ,  C12P21/06

    CPC分类号： C07K14/4756 ,  C07K14/475 ,  A61K38/00

    摘要： Disclosed are (1) a novel glia activating factor which has glial cell growth promoting activity; (2) a glia activating factor containing a polypeptide represented by SEQ ID NO: 1 or a mutein thereof having activity of the factor; (3) a DNA containing a polynucleotide coding for a glia activating factor represented by SEQ ID NO: 10; (4) a host transformed with a vector containing the DNA described in (3); and (5) a method for producing the above glia activating factor which comprises cultivating the transformant described in (4) in a medium accumulating the glia activating factor in a culture broth, and collecting the resulting glia activating factor.

    摘要翻译： 公开了（1）具有神经胶质细胞生长促进活性的新型神经胶质激活因子; （2）含有由SEQ ID NO：1表示的多肽或具有该因子活性的突变蛋白的胶质激活因子; （3）含有编码由SEQ ID NO：10表示的神经胶质激活因子的多核苷酸的DNA; （4）用含有（3）所述DNA的载体转化的宿主; （5）上述胶原激活因子的制造方法，其特征在于，在培养液中培养上述（4）所述的转化体后，在培养液中积聚神经胶质细胞活化因子，收集所形成的神经胶质细胞活化因子。

    Electricity generation equipment management system
    10.
    发明授权
    Electricity generation equipment management system 失效

    公开(公告)号：US07133852B2

    公开(公告)日：2006-11-07

    申请号：US09976259

    申请日：2001-10-12

    申请人： Tsutomu Kurokawa ,  Shigeaki Sato ,  Yoshiteru Misumi

    发明人： Tsutomu Kurokawa ,  Shigeaki Sato ,  Yoshiteru Misumi

    IPC分类号： G06Q99/00

    CPC分类号： G06Q50/06 ,  H04Q9/00 ,  H04Q2209/50 ,  H04Q2209/60 ,  Y02E40/76 ,  Y04S10/54 ,  Y04S10/545 ,  Y04S10/60

    摘要： A generator unit is installed locally to supply power to an electricity consumer. A management center monitors operation status of the generator unit and monitors the amount of electricity supplied to the electricity consumer by the generator unit. A service company performs maintenance and management for the generator unit based on instructions from the management center or the operation status of the generator unit. An electricity provider operating the generator unit bills the electricity consumer for an electricity supply service fee based on information sent to the management center. The resulting electricity generation equipment management system maintains and manages a generator unit without placing a burden on an electricity consumer, allowing efficient billing and payment of electricity supply service fees.